Celecoxib attenuates hepatocellular proliferative capacity during hepatocarcinogenesis by modulating a PTEN/NF-κB/PRL-3 pathway

Zhang, Cong; Zhou, Junxuan; Hu, Junjie; Sheng, Lei; Yuan, Ming; Chen, Liang; Wang, Guihong; Qiu, Zhenpeng

doi:10.1039/c9ra00429g

Cited by 2 publications

(2 citation statements)

References 49 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, USP4, which is elevated in gastric and rectal cancer, interacts with PRL-3 and increases the stability of PRL-3, promoting NF-κB signaling and cell viability [ 51 , 60 ]. Celecoxib, a promising candidate for anticancer therapy, upregulates PTEN protein expression in mouse hepatoma tissues while downregulating NF-κB and PRL-3 protein expression, ultimately attenuating liver cell proliferation [ 87 ].…”

Section: Prl-3 In Cancermentioning

confidence: 99%

Protein Tyrosine Phosphatase PRL-3: A Key Player in Cancer Signaling

Liu,

Li,

Shi

et al. 2024

Biomolecules

View full text Add to dashboard Cite

Protein phosphatases are primarily responsible for dephosphorylation modification within signal transduction pathways. Phosphatase of regenerating liver-3 (PRL-3) is a dual-specific phosphatase implicated in cancer pathogenesis. Understanding PRL-3’s intricate functions and developing targeted therapies is crucial for advancing cancer treatment. This review highlights its regulatory mechanisms, expression patterns, and multifaceted roles in cancer progression. PRL-3’s involvement in proliferation, migration, invasion, metastasis, angiogenesis, and drug resistance is discussed. Regulatory mechanisms encompass transcriptional control, alternative splicing, and post-translational modifications. PRL-3 exhibits selective expressions in specific cancer types, making it a potential target for therapy. Despite advances in small molecule inhibitors, further research is needed for clinical application. PRL-3-zumab, a humanized antibody, shows promise in preclinical studies and clinical trials. Our review summarizes the current understanding of the cancer-related cellular function of PRL-3, its prognostic value, and the research progress of therapeutic inhibitors.

show abstract

Section: Prl-3 In Cancermentioning

confidence: 99%

Protein Tyrosine Phosphatase PRL-3: A Key Player in Cancer Signaling

Liu,

Li,

Shi

et al. 2024

Biomolecules

View full text Add to dashboard Cite

show abstract

“…183 Interestingly, Zhang et al reported that celecoxib increased PTEN protein expression while inhibiting NF-κB and phosphatase of regenerating liver-3 expression levels in HCCafflicted mouse livers. 184 A compelling study by Guo et al demonstrated that administration of celecoxib post-diagnosis led to better overall survival rates in cancer patients, particularly those exhibiting positive PTGS2 expression combined with a phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutation. 185 Overall, the momentum of clinical trials investigating the role of celecoxib in cancer therapy is intensifying.…”

Section: Dna Damage Responsementioning

confidence: 99%

Drug repurposing for cancer therapy

Xia,

Sun,

Huang

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Cancer, a complex and multifactorial disease, presents a significant challenge to global health. Despite significant advances in surgical, radiotherapeutic and immunological approaches, which have improved cancer treatment outcomes, drug therapy continues to serve as a key therapeutic strategy. However, the clinical efficacy of drug therapy is often constrained by drug resistance and severe toxic side effects, and thus there remains a critical need to develop novel cancer therapeutics. One promising strategy that has received widespread attention in recent years is drug repurposing: the identification of new applications for existing, clinically approved drugs. Drug repurposing possesses several inherent advantages in the context of cancer treatment since repurposed drugs are typically cost-effective, proven to be safe, and can significantly expedite the drug development process due to their already established safety profiles. In light of this, the present review offers a comprehensive overview of the various methods employed in drug repurposing, specifically focusing on the repurposing of drugs to treat cancer. We describe the antitumor properties of candidate drugs, and discuss in detail how they target both the hallmarks of cancer in tumor cells and the surrounding tumor microenvironment. In addition, we examine the innovative strategy of integrating drug repurposing with nanotechnology to enhance topical drug delivery. We also emphasize the critical role that repurposed drugs can play when used as part of a combination therapy regimen. To conclude, we outline the challenges associated with repurposing drugs and consider the future prospects of these repurposed drugs transitioning into clinical application.

show abstract

Celecoxib attenuates hepatocellular proliferative capacity during hepatocarcinogenesis by modulating a PTEN/NF-κB/PRL-3 pathway

Abstract: Celecoxib modulates the PTEN/NF-κB/PRL-3 pathway during hepatocarcinogenesis in vivo.

Cited by 2 publications

References 49 publications

Protein Tyrosine Phosphatase PRL-3: A Key Player in Cancer Signaling

Protein Tyrosine Phosphatase PRL-3: A Key Player in Cancer Signaling

Drug repurposing for cancer therapy

Contact Info

Product

Resources

About